Date: 2017-09-29
Type of information: Clinical research agreement
Compound: TGR-1202 (umbralisib)
Company: TG Therapeutics (USA - NY) Fast Forward (USA - NY)
Therapeutic area: Neurodegenerative diseases
Type agreement: clinical research
Action mechanism:
- phosphoinositide 3-kinase (PI3K) inhibitor TGR-1202 (formerly known as RP5264) is an orally available PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of phosphoinositide 3-kinase. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-cell lymphocytes. Inhibition of PI3K delta signaling with TGR-1202 has demonstrated robust activity in numerous pre-clinical models and primary cells from patients with hematologic malignancies.
Disease: progressive multiple sclerosi
Details:
- • On September 29, 2017, TG Therapeutics announced today that it has entered into a sponsored research agreement with the National Multiple Sclerosis Society through Fast Forward, its not for profit subsidiary. Under the agreement, Fast Forward will provide funding to TG Therapeutics to further the preclinical development of TGR-1202 (umbralisib), the company's novel PI3K-delta inhibitor, as a potential oral treatment option for progressive forms of multiple sclerosis (PMS). TGR-1202 was selected by Fast Forward through a competitive selection process based on its potential in the treatment of PMS. Dr. Lawrence Steinman, MD, of Stanford University will lead the research team on this effort.
Financial terms:
Latest news:
Is general: Yes
